Sign in
Enrolling by invitationNo phase

Automated lymphatic drainage massage device for people with obstructive sleep apnea

Tests a lymph drainage device on brain waste clearance in obstructive sleep apnea.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
Automated Manual Lymphatic Drainage Therapy to Improve Glymphatic Function in OSA Patients
Status
Enrolling by invitation
People taking part
15 people, planned
Started
24 Nov 2025
Expected to end
Dec 2026
Type of study
Interventional
Treatments tested
  • Automated manual lymphatic drainage therapy (AMLDT) device
Record updated
10 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 or older with obstructive sleep apnea who already use CPAP well. They will use a lymphatic drainage device (Neuroglide) every night for 1 month.

Age
50 years and older
Sex
All sexes
Disease stage
Diagnosed obstructive sleep apnea (breathing stops during sleep because the airway closes).
Earlier treatment
Must be on stable, effective CPAP therapy, used as prescribed, for at least 6 months. Medicines for other health or mental health conditions must be stable for at least 3 months, with no changes planned during the trial.

Main reasons for not taking part

  • Chronic kidney disease (GFR < 60 mL/min/1.73 m² for 3 months or more)
  • Other sleep disorders, circadian rhythm disorder or shift work
  • Chronic neurological disorders such as multiple sclerosis, epilepsy or ALS
  • Atrial fibrillation, high PVC burden, pacemakers, adhesive allergies, or CPAP masks with forehead support
  • Kokmen short test of mental status < 34, active infection, cancer not in remission, or lymphatic problems

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age 50 years and older
  • Diagnosed with obstructive sleep apnea
  • On stable, effective, and compliant CPAP therapy for a minimum of 6 months
  • Willing and able to provide informed consent
  • Willing and able to use automated manual lymphatic drainage device (Neuroglide) nightly for 1-month and participate in at-home sleep monitoring
  • Stable on a medication regimen for comorbid medical or mental health disorders for at least 3 months and not planning to undergo therapy adjustment during trial

Who cannot take part

  • Chronic neurological disorders (e.g. Multiple sclerosis, epilepsy, neurodegenerative disorders, ALS), due to their impact on biomarkers. History of headache (<15 days a month) and stroke (over 6 months prior to enrollment) are allowed
  • Acute cardiopulmonary disorders, infections, injury at/near the application site, abnormal lymphatic system due to previous surgery involving lymphatics or chronic lymphedema, acute inflammatory process (e.g. recent knee/hip surgery, upper respiratory tract infection, cancer not in remission)
  • Other primary sleep disorders aside from OSA (i.e., narcolepsy, REM Sleep behavior disorder, chronic insomnia, restless legs syndrome), circadian rhythm disorder or shift work
  • Physical limitations preventing the use or function of Somfit, including forehead skin lesions, history of adhesive allergies, implanted electronic devices (e.g. pacemakers) or the use of CPAP masks with forehead support/bar/pad (Fisher \& Paykel Vitera, Fisher \& Paykel Eson, ResMed Mirage Quattro, ResMed Ultra Mirage Full Face Mask, Philips Respironics ComfortGel Blue), because the forehead piece of the mask would prevent the appropriate application of Somfit for at-home sleep monitoring. Because Somfit algorithms are based on physiological signals that include heart rate and it has not been validated in patients with persistent arrhythmia, we will exclude patients with history of atrial fibrillation and high PVC burden to avoid inaccurate estimates
  • Kokmen short test of mental status < 34 (concern for mild cognitive impairment)
  • Chronic kidney disease (glomerular filtration rate (GFR) < 60 mL/min/1.73 m² for 3 months or more), due to its potential impact on serum biomarker clearance
  • Physical limitations preventing the use of Neuroglide device (e.g. inability to lay on the back due to pain, inability to setup the device due to limb dysfunction/weakness)
  • Inability to comply with study procedures

Where in United States

  • Mayo ClinicRochester, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The purpose of this research is to investigate whether enhancing systemic lymphatic drainage improves glymphatic function in patients with obstructive sleep apnea (OSA).

The group in the trial

  • InterventionOther group

    Open-Label intervention

    Treatment: Automated manual lymphatic drainage therapy (AMLDT) device

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Using Automated Manual Lymphatic Drainage Therapy to Optimize Glymphatic Function in Patients With Obstructive Sleep Apnea: Proof-of-Concept Open-Label Trial
Plain-language title
Automated lymphatic drainage massage device for people with obstructive sleep apneaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
10 September 2026